Primary Site >> Pancreatic Cancer
Gene >> BRAF
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: BRAF and K-ras gene mutations in human pancreatic cancers. PMID: 12969789 Ref: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. PMID: 14507635 |
Ref: Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. PMID: 15367885 Ref: BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. PMID: 15613458 |
Ref: The genetics of susceptibility to cutaneous melanoma. PMID: 15883616 |
Ref: Molecular pathogenesis of pancreatic cancer. PMID: 16549325 Ref: Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. PMID: 16598499 |
Ref: BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. PMID: 17097223 Ref: Molecular diagnostic testing as an adjunct to morphologic evaluation of pancreatic ductal system brushings: potential augmentation for diagnostic sensitivity. PMID: 17351944 Ref: Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. PMID: 17353198 |
Ref: PIK3CA cancer mutations display gender and tissue specificity patterns. PMID: 18022911 Ref: PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. PMID: 18343945 Ref: Histopathological features of patients with chronic pancreatitis due to mutations in the PRSS1 gene: evaluation of BRAF and KRAS2 mutations. PMID: 18946221 |
Ref: Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas. PMID: 18813127 Ref: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. PMID: 19372556 Ref: Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. PMID: 19440145 Ref: Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PMID: 19826477 Ref: Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. PMID: 19893451 |
Ref: Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas. PMID: 21698197 Ref: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. PMID: 21734707 Ref: Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. PMID: 21945955 Ref: GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. PMID: 21998291 Ref: Molecular pathogenesis of pancreatic cancer and clinical perspectives. PMID: 22116519 |
Ref: Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. PMID: 22041919 Ref: Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity. PMID: 22833572 Ref: KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. PMID: 22871572 Ref: Intraductal tubulopapillary neoplasm of the pancreas with somatic BRAF mutation. PMID: 26181322 |
Ref: Twenty-fourth annual Pezcoller symposium: Molecular basis for resistance to targeted agents. PMID: 23222297 Ref: Trametinib: first global approval. PMID: 23846731 |
Ref: Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. PMID: 24189171 Ref: Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. PMID: 24293293 Ref: Case report: Intraductal tubulopapillary neoplasm of the pancreas with unique clear cell phenotype. PMID: 24443801 Ref: IQGAP1 selectively interacts with K-Ras but not with H-Ras and modulates K-Ras function. PMID: 24462863 Ref: Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. PMID: 24604757 Ref: Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PMID: 24978597 Ref: Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. PMID: 25266736 |
Ref: Molecular landscape of pancreatic cancer: implications for current clinical trials. PMID: 11051691 Ref: Identification of dysregulated pathways associated with pancreatic cancer by survival analysis. PMID: 25333741 Ref: A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. PMID: 25500057 Ref: Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer. PMID: 25699241 Ref: Molecular landscape of pancreatic cancer: implications for current clinical trials. PMID: 25714017 Ref: Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. PMID: 25797243 Ref: Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. PMID: 25855536 Ref: Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. PMID: 26227479 Ref: A combination of molecular markers and clinical features improve the classification of pancreatic cysts. PMID: 26253305 Ref: Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature. PMID: 26464736 Ref: A case of MUC5AC-positive intraductal neoplasm of the pancreas classified as an intraductal tubulopapillary neoplasm? PMID: 26586167 |
Ref: The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. PMID: 26314551 Ref: Intraductal tubulopapillary neoplasm of the bile duct: A case report and review of the published work. PMID: 26459784 Ref: Mutational spectrum of intraepithelial neoplasia in pancreatic heterotopia. PMID: 26626780 Ref: Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. PMID: 26732095 Ref: KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review. PMID: 26927447 Ref: Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. PMID: 27041411 Ref: [Clinicopathological characteristics of colorectal carcinoma in the elderly]. PMID: 27215512 |
Ref: Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. PMID: 27725226 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. PMID: 28456055 Ref: Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells. PMID: 28500236 Ref: Intraductal tubulopapillary neoplasm accompanied by invasive carcinoma of the pancreas: A case report and review of the literature. PMID: 28529742 Ref: A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. PMID: 28576749 Ref: Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. PMID: 29113235 Ref: Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors. PMID: 29259370 Ref: Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. PMID: 29270287 Ref: Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents. PMID: 29354330 Ref: The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. PMID: 29507555 |
Ref: A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms. PMID: 28884748 Ref: RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. PMID: 29059158 Ref: Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. PMID: 29103024 Ref: Intraductal Tubulopapillary Neoplasm of the Pancreas: An Overview. PMID: 29494224 Ref: [ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017]. PMID: 29642252 Ref: Targeting oncogenic Ras by the Clostridium perfringens toxin TpeL. PMID: 29662661 Ref: Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. PMID: 29903880 Ref: Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. PMID: 30065098 Ref: Intrapancreatic recurrence of intraductal tubulopapillary neoplasm (ITPN) 16 years after the initial surgery for noninvasive ITPN: a case report. PMID: 30116990 Ref: Laparoscopic pancreaticoduodenectomy for metastatic pancreatic melanoma: A case report. PMID: 30383642 |